Abetimus
- Generic Name
- Abetimus
- Drug Type
- Biotech
- CAS Number
- 167362-48-3
- Unique Ingredient Identifier
- P3UVQ22SHK
Overview
Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
Background
Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
Indication
Investigated for use/treatment in kidney disease and systemic lupus erythematosus.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath